"Designing Growth Strategies is in our DNA"
The global Huntington’s disease treatment market size was valued at USD 848.0 million in 2022 and is projected to grow from USD 945.8 million in 2023 to USD 2,932.2 million by 2030, exhibiting a CAGR of 17.5% during the forecast period.
Huntington’s Disease (HD) is a rare inherited disease in which the nerve cells of the brain start degenerating over time. It is a progressive disorder and has no definite cure. However, its symptoms, which affect the patient mentally as well as physically, can be managed. Some of the symptoms include mental or behavioral changes such as apathy, depression, irritability, anxiety, obsessive-compulsive disorder (OCD), and, more rarely, psychosis. Physical symptoms include jerky movements in hands, fingers, and in facial muscles, which are called chorea. Chorea gets worse over time but can be managed with the help of two drugs that have been approved for this condition – Tetrabenazine and Deutetrabenazine. These drugs are currently the only approved drugs for the treatment of chorea associated with this disease.
Huntington’s disease is prevalent in regions such as North America and Europe, which offer a huge potential for market players to introduce novel drugs over the forecast period. Many research institutes and government organizations are providing research grants and technological support to accelerate the development of pipeline candidates. For instance, AMT-130 is a micro-RNA drug designed by uniQure to silence the Huntingtin gene and inhibit the production of the mutant Huntingtin protein. Such novel approaches initiated by market players will drive the global Huntington’s disease treatment market growth during the forecast period.
Decline in Hospital Visits During COVID-19 Led to Slower Market Growth
During COVID-19, a huge decline in non-COVID-19 related healthcare services and procedures was observed in light of restrictions imposed due to safety concerns. This was especially relevant for rare conditions such as Huntington’s disease treatment, which was considered non-essential.
The market players experienced huge declines in their product revenue due to diminished demand for this disease treatment solution.
However, consumers in the U.K. and Germany, which are key markets, utilized online pharmacies to procure repeat medications such as oral medications. This allowed companies to minimize the negative impact of the pandemic to some extent. As per quarterly report published by Teva Pharmaceutical Industries Ltd., the prescription for AUSTEDO drug increased from 156,994 in 2021 to almost 240,527 in 2022. Such trends indicate that the market is poised for steady growth in the number of patients for Huntington’s disease treatment during the forecast period.
Request a Free sample to learn more about this report.
Novel Approaches Targeting Core Symptoms of the Disease to Create Growth Opportunities
Some of the prevailing trends witnessed in the global market are rising R&D initiatives of market players to introduce novel therapeutic options, which can target the core symptoms of the disease. One of the novel approaches to control or manage the symptoms of this condition is the lowering and modification of the Huntington (HTT) gene expression or prolonging the neurotransmission or electric synaptic transmission.
Thus, it can be witnessed that research & development initiatives, which include precision medicines and gene therapy for the treatment of core disease symptoms can contribute to the market’s growth prospects.
Rising Prevalence of the Disease is Likely to Propel Market Growth
The rising prevalence of this disease in various regions, especially in the U.S. and key countries of Europe is a key factor augmenting the market growth. The disease is an inherited neurodegenerative disorder and has no definite cure. However, its symptoms can be managed. One of the first and core physical symptoms is the involuntary jerky movements called chorea that affect facial and limb muscles and get worse with time.
The increase in prevalence of the disease will drive the demand for more effective therapeutic measures to control and manage associated symptoms. These factors will propel the market growth during 2023-2030.
Growing Government Initiatives to Increase Awareness of the Disease to Fuel Market Growth
Globally, government bodies are actively introducing new programs, campaigns, and beneficiary schemes to increase awareness regarding this condition, and educate patients about available treatment options. These initiatives are expected to lead to an increase in the number of cases diagnosed of the disease, leading to a rise in demand for innovative drugs.
Lack of Approved Drugs and Stringent Regulatory Policies May Hinder the Market Growth
Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Chorea is one of the core and first physical symptoms observed in a patient and gets worse with time if left untreated. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs.
Such restrictions from regulatory agencies may influence the interest of market players, leading to slower market growth during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Tetrabenazine Segment Dominated the Market Due to High Adoption Rate in 2022
By drug, the market is segmented into tetrabenazine, deutetrabenazine, and others.
The tetrabenazine segment dominated the global Huntington’s disease treatment market share in 2022. The drug has been in the market since 2007 and has a higher adoption rate due to the availability of its generic version. For instance, in March 2020, Apotex Inc. launched a generic equivalent of tetrabenazine in the market which is indicated for the treatment of chorea associated with this condition. The availability of the generic version of this drug at a comparatively lower price for such rare diseases will lead to higher adoption and demand, which is likely to contribute to the market growth during the forecast period.
The deutetrabenazine segment is estimated to grow at a comparatively higher CAGR due to minimal side effects associated with the drug. Moreover, the adherence rate of this drug refill is comparatively higher than tetrabenazine. For instance, as per an article published by BioNews, Inc. in January 2022, the proportion of patients with an adherence rate of AUSTEDO (deutrabenazine) refill is higher i.e., 78.5% compared to Xenazine (tetrabenazine) i.e., 69.3% was observed in a group of patient population. Such high adoption rate of deutetrabenazine among the patient population is expected to drive the segment’s growth during the forecast period.
Others segment includes pipeline candidates, which will exhibit steady growth over 2023-2030, after their prospective launches.
Higher Procurement of Therapeutics Through Hospital Pharmacies Led to Segment’s Dominance in 2022
On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.
Hospital pharmacies segment accounted for the largest share of the global market in 2022 due to the need for the procurement of prescription therapeutics from hospital pharmacies. The dominance of the segment is attributable to the fact that majority of the medications for the treatment can only be prescribed after thorough examinations by trained medical professionals at these institutions.
The drug stores & retail pharmacies segment held the second-largest market share in 2022, owing to the usage of the settings for the procurement of prescription refills. The online pharmacies segment will grow at the highest CAGR during the forecast period due to increased adoption of digital pharmaceutical platforms, which makes the medication procurement process easy by delivery at the doorstep. Hence, all these factors cumulatively will drive the global market growth.
North America Huntington’s Disease Treatment Market Size, 2022 (USD Million)
To get more information on the regional analysis of this market, Request a Free sample
In terms of region, the global market is segmented into North America, Europe, Asia Pacific, and the rest of the world.
The North America market for Huntington’s disease treatment was valued at USD 787.3 million in 2022. The region is likely to dominate the market throughout the forecast period due to the substantial awareness amongst the population regarding the disease and rising support from many public and private organizations through research grants to accelerate the study of this disease. For instance, as per Huntington’s Disease Society of America (HDSA) 2021 publication, HDSA awarded five research grants of a total of more than USD 78,000 to the Huntington’s Disease Human Biology Project, a research initiative focused on better understanding and accelerating research for this disease in people. Such initiatives are likely to contribute to market growth during the forecast period.
Europe held a significant market share, due to the rising initiatives from the government to improve the quality of care and treatment of HD patients, which has aided to the market's growth in Europe. In December 2020, the European Huntington Association (EHA) and the European Federation of Neurological Associations (EFNA) with financial support from F. Hoffmann-La Roche Ltd. held a virtual policy roundtable to enable the necessary steps in order to provide quality care and treatment for people living with this disease.
Asia Pacific and the rest of the world, which includes Latin America and the Middle East & Africa, are likely to grow at a comparatively lower CAGR due to the comparatively lower prevalence rate of this condition amongst the population. As per an article published in the Open Access Text (OAT) in 2018, the prevalence rate in Americas, Europe, and Australia is 8-12 per 100,000 people whereas it is significantly lower in Asia and Africa with an estimate of 0.5 per 100,000 and even lower in African countries such as South Africa. Hence, the low prevalence rate translates into lower adoption and slower growth of the market across these regions. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.
Teva Pharmaceutical Industries Ltd and H. Lundbeck A/S Held Peak Position in 2021 due to Robust Product Sales
In terms of competitive landscape, Teva Pharmaceutical Industries Ltd. is one of the key players dominating the market. AUSTEDO (Deutetrabenazine) is a drug approved by the U.S. FDA in April 2017 and since then, the drug is exhibiting steady growth. Xenazine (Tetrabenazine) is another drug approved for the same indication in 2007 and is commercialized by H. Lundbeck A/S and Bausch Health Companies Inc.
Some other players which hold substantial shares in the market include Sun Pharmaceutical Industries, Inc., Lupin, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, and others. These companies are generic manufacturers of tetrabenazine. The lack of approved products in the market has led to the development of an interest for other market players to develop new drugs to meet the clinical demand from the growing patient population. Market players, such as Neurocrine Biosciences, Inc., Prilenia Therapeutics, Novartis AG, SOM Biotech (Spain), uniQure, Annexon Biosciences, and Hoffmann-La Roche, are focusing on the acceleration of the development of their pipeline candidates. New product launches would contribute to the global Huntington’s disease therapeutics market growth.
An Infographic Representation of Huntington’s Disease Treatment Market
To get information on various segments, share your queries with us
The research report provides qualitative and quantitative insights on the global market and a detailed analysis of global market size & growth rate for all possible segments in the market. Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are the prevalence of the disease by key regions/countries, key industry developments, pipeline analysis, economic cost burden for the treatment of the disease, regulatory and reimbursement scenario, by key regions, and the impact of COVID-19 on the global market.
CAGR of 17.5% from 2023 to 2030
Value (USD million)
By Drug, Distribution Channel, and Region
By Distribution Channel
Fortune Business Insights says that the global market size was USD 848.0 million in 2022 and is projected to reach USD 2,932.2 million by 2030.
In 2022, the North America market stood at USD 787.3 million.
The market will grow at a CAGR of 17.5% in the forecast period (2023-2030).
Tetrabenazine segment is expected to be the leading segment in this market during the forecast period.
Growing prevalence of Huntington’s disease and active support from government authorities to increase awareness on its treatment measures are some of the major factors driving the global market.
Teva Pharmaceutical Industries Ltd, H. Lundbeck A/S, and Bausch Health Companies Inc. are the leading market players in the global market.
North America dominated the market in 2022.
Growing R&D investments of market players to accelerate the development of pipeline candidates are expected to drive the demand for these drugs.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry